Recently, several studies have clarified that N6-methyladenosine (m6A) methylase (METTL3) plays oncogenic roles in radiosensitivity in glioblastoma 15, gastric cancer 16, and hypopharyngeal squamous cell carcinoma 17, representing an opportunity for the development of METTL3-targeted therapies for NPC. This evidence concerns the gene METTL3 and hypopharynx squamous cell carcinoma.